- Home
- RS vs INAB Comparison
RS vs INAB Comparison
Compare RS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RS
- INAB
- Stock Information
- Founded
- RS 1939
- INAB 2016
- Country
- RS United States
- INAB United States
- Employees
- RS N/A
- INAB N/A
- Industry
- RS Metal Fabrications
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- RS Industrials
- INAB Health Care
- Exchange
- RS Nasdaq
- INAB Nasdaq
- Market Cap
- RS 15.5B
- INAB 24.0M
- IPO Year
- RS 1994
- INAB 2021
- Fundamental
- Price
- RS $269.09
- INAB $0.25
- Analyst Decision
- RS Hold
- INAB Strong Buy
- Analyst Count
- RS 5
- INAB 3
- Target Price
- RS $344.00
- INAB $7.75
- AVG Volume (30 Days)
- RS 352.1K
- INAB 727.4K
- Earning Date
- RS 02-13-2025
- INAB 11-12-2024
- Dividend Yield
- RS 1.64%
- INAB N/A
- EPS Growth
- RS N/A
- INAB N/A
- EPS
- RS 18.25
- INAB N/A
- Revenue
- RS $14,045,700,000.00
- INAB N/A
- Revenue This Year
- RS N/A
- INAB N/A
- Revenue Next Year
- RS $1.34
- INAB N/A
- P/E Ratio
- RS $14.74
- INAB N/A
- Revenue Growth
- RS N/A
- INAB N/A
- 52 Week Low
- RS $261.16
- INAB $0.22
- 52 Week High
- RS $342.20
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- RS 26.58
- INAB 39.26
- Support Level
- RS $302.62
- INAB $0.28
- Resistance Level
- RS $310.14
- INAB $0.32
- Average True Range (ATR)
- RS 7.47
- INAB 0.03
- MACD
- RS -5.49
- INAB -0.01
- Stochastic Oscillator
- RS 12.96
- INAB 13.73
About RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.